2,398 results match your criteria: "Toulouse University hospital[Affiliation]"
Front Cardiovasc Med
September 2024
Department of Anesthesiology and Intensive Care, University Hospital of Toulouse, Toulouse, France.
Introduction: Low cardiac output syndrome (LCOS) is a common complication in cardiac surgery, and we evaluated the incidence of its early occurrence after mitral and tricuspid combined cardiac surgery and its associated risk factors.
Material And Method: Retrospective, single institution study. We included 88 consecutive adult patients with severe mitral insufficiency scheduled for elective mitral and tricuspid valve replacement surgery between January 2015 and November 2018.
J Allergy Clin Immunol Pract
January 2025
Department of Respiratory Medicine, Faculty of Medicine, Toulouse University Hospital, Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity) INSERM UMR1291-CNRS UMR5051-Université Toulouse III, CRISALIS F-CRIN, Toulouse, France. Electronic address:
J Fr Ophtalmol
October 2024
Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, place Baylac, 31059 Toulouse cedex, France; Faculty of Medicine, University of Toulouse III, Toulouse, France.
Eur J Cancer
November 2024
University of Lorraine, Department of Hepato-Gastroenterology and digestive oncology, Nancy University Hospital, Nancy, France. Electronic address:
Background: Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis. The POLO trial showed that olaparib (PARP inhibitor) improved progression-free survival (PFS) but not overall survival (OS), when used as maintenance therapy after ≥ 16 weeks of disease control with first-line platinum-based chemotherapy in patients with germline (g) BRCA 1 or 2 pathogenic variants (PV) metastatic PDAC. However, real-world data on the effectiveness of olaparib are missing.
View Article and Find Full Text PDFClin Exp Allergy
October 2024
Innovation & Science Department, Stallergenes Greer, Antony, France.
Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy is a central component in the management of asthma, it does not enable control of asthma symptoms in all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic asthma, have benefited from biological therapies.
View Article and Find Full Text PDFWhat Is This Study About?: This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines called lorlatinib (Lorbrena) and crizotinib (Xalkori) for people with advanced non-small cell lung cancer (NSCLC) who had not been treated yet. Everyone in the study had changes in a called anaplastic lymphoma kinase, or , in their cancer cells.
View Article and Find Full Text PDFBrain Inj
January 2025
Department of Neurology, Toulouse University Hospital, Toulouse, France.
Purpose: We conducted a proof-of-concept study to evaluate the effects of galantamine treatment versus placebo combined to cognitive rehabilitation (CR) after stroke.
Materials And Methods: In this 12-week, double blinded, randomized, controlled trial, patients were assigned to either combined approach of galantamine and CR (G-CR) or placebo and CR (P-CR). Primary outcome was the proportion of patients who crossed over from vascular cognitive disorder (VCD) to no-VCD at 12 weeks.
Curr Opin Cardiol
November 2024
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium.
J Prev Alzheimers Dis
October 2024
D. Angioni, Institut Hospitalo Universitaire HealthAge, Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France,
Recent positive results of three phase III anti-amyloid monoclonal antibody trials are transforming the landscape of disease-modifying therapeutics for Alzheimer's disease, following several decades of failures. Indeed, all three trials have met their primary endpoints. However, the absolute size of the benefit measured in these trials has generated a debate on whether the change scores observed on clinical outcome assessments represent a clinically meaningful benefit to patients.
View Article and Find Full Text PDFBiol Direct
September 2024
FLAMES Team, Restore Institute, Inserm, Toulouse III Paul Sabatier University, 4Bis Av. H. Curien, 31100, Toulouse, France.
Arch Pediatr
September 2024
AP-HP, Paris Saclay University, INSERM; Centre de Référence des Maladies Rares du Calcium et du Phosphore, Service d'Endocrinologie et diabète de l'enfant, Filières Santé Maladies Rares OSCAR, ERN endoRARE et BOND, Hôpital Bicêtre Paris-Saclay; U1185 physiologie et physiopathologie endocrinienne; Le Kremlin Bicêtre, France.
Aging Dis
September 2024
Department of Clinical and Health Psychology and Research Methodology, Psychology Faculty, University of the Basque Country (UPV/EHU), Donostia-San Sebastián, Gipuzkoa, Spain.
Myotonic dystrophy type 1 (DM1) is an inherited neuromuscular disorder often considered a model of accelerated aging due to the early appearance of certain age-related clinical manifestations and cellular and molecular aging markers. Frailty, a state of vulnerability related to aging, has been recently studied in neurological conditions but has received considerably less attention in neuromuscular disorders. This narrative review aims to describe 1) the common characteristics between Fried's frailty phenotype criteria (muscular weakness, slow gait speed, weight loss, exhaustion/fatigue, and low physical activity) and DM1, and 2) the psychological and social factors potentially contributing to frailty in DM1.
View Article and Find Full Text PDFJ Am Soc Nephrol
September 2024
Inflammation, Complement and Cancer Team, Cordeliers Research Center, Institut National de la Santé et de la Recherche Médicale (INSERM) Unité Mixte de Recherche (UMR) S1138, Paris, France.
Calcif Tissue Int
November 2024
Rare Disease Genomic Medicine Department, CHU Necker-Enfants Malades, INSERM UMR1163, Institut Imagine, Université Paris-Cité, Paris, France.
Int J Stroke
October 2024
Department of Neurology, University Hospitals Leuven, Leuven, Belgium.
Background: In patients with an acute ischemic stroke, the penumbra is defined as ischemic tissue that remains salvageable when reperfusion occurs. However, the expected clinical recovery congruent with penumbral salvage is not always observed.
Aims: We aimed to determine whether the magnetic resonance imaging (MRI)-defined penumbra includes irreversible neuronal loss that impedes expected clinical recovery after reperfusion.
Blood Cancer J
September 2024
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Mantle cell lymphoma (MCL) is genetically characterized by the IG::CCND1 translocation mediated by an aberrant V(D)J rearrangement. CCND1 translocations and overexpression have been identified in occasional aggressive B-cell lymphomas with unusual features for MCL. The mechanism generating CCND1 rearrangements in these tumors and their genomic profile are not known.
View Article and Find Full Text PDFVision (Basel)
September 2024
Ophthalmology Department, Pierre-Paul Riquet Hospital, Toulouse University Hospital, 31059 Toulouse, France.
Int J Cancer
January 2025
Otolaryngology, Head and Neck Surgery Department, University Cancer Institute Toulouse and Toulouse University Hospital, Larrey Hospital, Toulouse, France.
Fr J Urol
December 2024
Department of Urology, Toulouse University Hospital, 1, avenue du Professeur-Jean-Poulhès, 31400 Toulouse, France.
Therapie
September 2024
Regional Pharmacovigilance Centre, University Hospital of Nancy, 54511 Vandœuvre-lès-Nancy, France. Electronic address:
Neurology
October 2024
From the Department of Radiology and Nuclear Medicine (L.L., S.I., L.E.C., M.T., A.M.W., F.B.), Amsterdam University Medical Centre, Vrije Universiteit; Amsterdam Neuroscience (L.L., S.I., L.E.C., A.M.W., H.M.), Brain Imaging, Amsterdam, The Netherlands; Department of Neurology and Laboratory of Neuroscience (A.M., F.V., N.T., V.S.), IRCCS Istituto Auxologico Italiano, Milan, Italy; Department of Radiology (S.I.), Copenhagen University Hospital Rigshospitalet; Cerebriu A/S (S.I.), Copenhagen, Denmark; Clinical Memory Research Unit (L.E.C.), Department of Clinical Sciences, Lund University, Malmö, Sweden; Department of Advanced Biomedical Sciences (M.T.), University "Federico II," Naples, Italy; Department of Psychiatry and Neurochemistry (K.B., C.H.S.), Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the University of Gothenburgn; Clinical Neurochemistry Laboratory (K.B.), Sahlgrenska University Hospital, Mölndal, Sweden; Neuroradiology Department (C.D.P.), University Hospital of Coventry and Warwickshire (UHCW), Coventry; GE HealthCare (C.F.), Amersham; Dementia Research Centre (N.C.F.), UCL Queen Square Institute of Neurology; UK Dementia Research Institute at University College London (N.C.F.), United Kingdom; Laboratory Alzheimer's Neuroimaging and Epidemiology (G.B.F.), IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy; University Hospitals and University of Geneva (G.B.F.); CIMC - Centre d'Imagerie Médicale de Cornavin (S.H.), Place de Cornavin 18, Genève, Switzerland; Department of Surgical Sciences (S.H.), Radiology, Uppsala University, Sweden; Department of Radiology (S.H.), Beijing Tiantan Hospital, Capital Medical University, P. R. China; Centro de Investigación y Terapias Avanzadas (P.M.-L.), Neurología, CITA-Alzheimer Foundation, San Sebastián, Spain; Centre for Clinical Brain Sciences (D.M., A.W., J.M.W.), The University of Edinburgh; Department of Psychiatry (J.O.B.), School of Clinical Medicine, CB2 0SP, University of Cambridge, United Kingdom; Department of Nuclear Medicine (P.P.), Toulouse University Hospital; ToNIC (P.P.), Toulouse NeuroImaging Center, University of Toulouse, Inserm, UPS, France; Edinburgh Dementia Prevention (C.R.), Centre for Clinical Brain Sciences, Outpatient Department 2, Western General Hospital, University of Edinburgh Brain Health Scotland (C.R.), Edinburgh, United Kingdom; Alzheimer Center Amsterdam (P.S., B.M.T., P.J.V.), Neurology, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc; Amsterdam Neuroscience (P.S., B.M.T., P.J.V.), Neurodegeneration, Amsterdam, The Netherlands; Takeda Pharmaceuticals Ltd. (A.J.S.), Cambridge, MA; Department of Medical Physics and Biomedical Engineering (C.H.S.), Centre for Medical Image Computing (CMIC), University College London (UCL); MRC Unit for Lifelong Health & Ageing at UCL (C.H.S.), University College London; School of Biomedical Engineering and Imaging Sciences (C.H.S.), King's College London, United Kingdom; Department of Pathophysiology and Transplantation (F.V., N.T., V.S.), "Dino Ferrari" Center, Università degli Studi di Milano, Milan, Italy; Alzheimer Center Limburg (P.J.V.), Department of Psychiatry and Neuropsychology, School of Mental Health and Neuroscience, 6229 GS, Maastricht University, The Netherlands; Division of Neurogeriatrics (P.J.V.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden; Department of Medicine (A.W.), Imperial College London; IXICO (R.W.), EC1A 9PN, London, United Kingdom; Université de Normandie (G.C.), Unicaen, Inserm, U1237, PhIND "Physiopathology and Imaging of Neurological Disorders", institut Blood-and-Brain @ Caen-Normandie, Cyceron, Caen, France; German Center for Neurodegenerative Diseases (DZNE) (M.E.), Munich, Germany; Ghent Institute for Functional and Metabolic Imaging (GIfMI) (H.M.), Ghent University, Belgium; Barcelonaβeta Brain Research Center (BBRC) (J.D.G.), Pasqual Maragall Foundation; CIBER Bioingeniería (J.D.G.), Biomateriales y Nanomedicina (CIBER-BBN), Madrid; IMIM (Hospital del Mar Medical Research Institute) (J.D.G.); Universitat Pompeu Fabra (J.D.G.), Barcelona, Spain; UK Dementia Research Institute Centre at the University of Edinburgh (J.M.W.); and Institutes of Neurology and Healthcare Engineering (F.B.), University College London, United Kingdom.
Background And Objectives: Vascular risk factors (VRFs) and cerebral small vessel disease (cSVD) are common in patients with Alzheimer disease (AD). It remains unclear whether this coexistence reflects shared risk factors or a mechanistic relationship and whether vascular and amyloid pathologies have independent or synergistic influence on subsequent AD pathophysiology in preclinical stages. We investigated links between VRFs, cSVD, and amyloid levels (Aβ) and their combined effect on downstream AD biomarkers, that is, CSF hyperphosphorylated tau (P-tau), atrophy, and cognition.
View Article and Find Full Text PDFPediatr Nephrol
February 2025
Heidelberg University, Medical Faculty Heidelberg, Department of Pediatrics I, University Children's Hospital, Im Neuenheimer Feld 430, 69120, Heidelberg, Germany.
Background: This study by the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) was designed to determine the incidence, risk factors, current management strategies, and outcomes of antibody-mediated rejection (ABMR) in pediatric kidney transplant recipients (pKTR).
Methods: We performed an international, multicenter, longitudinal cohort study of data reported to the Cooperative European Paediatric Renal Transplant Initiative (CERTAIN) registry. Three hundred thirty-seven pKTR from 21 European centers were analyzed.
JACC Cardiovasc Imaging
December 2024
Cardiovascular Center Aalst, OLV Clinic, Aalst, Belgium; Department of Cardiology, Lausanne University Hospital, Lausanne, Switzerland.
Background: Approximately one-half of the patients with angina and nonobstructive coronary artery disease (ANOCA) have evidence of coronary microvascular dysfunction (CMD).
Objectives: This study aims to characterize patients with ANOCA by measuring their minimal microvascular resistance and to examine the pattern of vascular remodeling associated with these measurements.
Methods: The authors prospectively included patients with ANOCA undergoing continuous thermodilution assessment.
Intensive Care Med
November 2024
Department of Anesthesia and Pain Management, University Health Network (UHN), Women's College Hospital, University of Toronto, Toronto Western Hospital, Toronto, Canada.
The management of cardiogenic shock is an ongoing challenge. Despite all efforts and tremendous use of resources, mortality remains high. Whilst reversing the underlying cause, restoring/maintaining organ perfusion and function are cornerstones of management.
View Article and Find Full Text PDFFront Oncol
August 2024
School of Infection & Immunity, University of Glasgow, Glasgow, United Kingdom.